Clinical Research
Opportunities
Penn Medicine is conducting studies to develop new ways to prevent, diagnose, and treat disease. You might be eligible to participate
Get Started
Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently added/updated trials
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety,
PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for
whom there are no further treatment options known to confer clinical benefit.
CTFFR and Prediction of Non-Significant CAD Lesions
In this prospective cohort study, 250 patients with suspected or known CAD and at least
one intermediate coronary lesion (50-70% stenosis) who had a NiFFR value greater than
0.80 underwent coronary computed tomography angiography (CCTA) with NiFFR assessment.
Patients were followed for one year to monitor for MACE
Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation
(HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for
peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in
children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil
(MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will
study how well this treatment works in patients with hematologic malignancies.
Penn Medicine experts answer questions from patient advocates and share groundbreaking medical developments happening at the University of Pennsylvania.
Please choose between Voice or SMS based delivery of verification code
or